Phytoconstituents as pharmacotherapeutics in rheumatoid arthritis: challenges and scope of nano/submicromedicine in its effective delivery

Rahman, Mahfoozur; Beg, Sarwar; Verma, Amita; Al-Abbasi, Fahad A.; Anwar, Firoz; Saini, Sumant; Akhter, Sohail; Kumar, Vikas

doi:10.1111/jphp.12661

Cited by 48 publications

(29 citation statements)

References 87 publications

(239 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[83][84][85] These bioactive compounds showed an inhibitory mechanism against inflammatory mediators, thereby preventing cartilage destruction in various animal studies. Besides the protective effect of these bioactive compounds, their bioavailability through oral delivery system is a great challenge for their potential RA treatment.…”

Section: Anti-arthritic Effectmentioning

confidence: 99%

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Ganesan

Ramalingam

Karthivashan

et al. 2018

IJN

135

View full text Add to dashboard Cite

Solid lipid nanoparticle (SLN) delivery systems have a wide applicability in the delivery of phyto-bioactive compounds to treat various chronic diseases, including diabetes, cancer, obesity and neurodegenerative diseases. The multiple benefits of SLN delivery include improved stability, smaller particle size, leaching prevention and enhanced lymphatic uptake of the bioactive compounds through oral delivery. However, the burst release makes the SLN delivery systems inadequate for the oral delivery of various phyto-bioactive compounds that can treat such chronic diseases. Recently, the surface-modified SLN (SMSLN) was observed to overcome this limitation for oral delivery of phyto-bioactive compounds, and there is growing evidence of an enhanced uptake of curcumin delivered orally via SMSLNs in the brain. This review focuses on different SLN and SMSLN systems that are useful for oral delivery of phyto-bioactive compounds to treat various chronic diseases.

show abstract

Section: Anti-arthritic Effectmentioning

confidence: 99%

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Ganesan

Ramalingam

Karthivashan

et al. 2018

IJN

135

View full text Add to dashboard Cite

show abstract

“…The available treatment for OA used in clinical practice mainly targets reduction of symptoms, protection of joint mobility, and limiting the failure of functional ability. Many researchers claimed that several herbal drugs and phytoconstituents used in the treatment of inflammatory arthritis improve OA symptoms [ 20 , 21 ]. Naringin shows various pharmacological effects; however, no evidence has been presented demonstrate the protective effect of naringin in OA treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Osteoarthritis (OA) is a common musculoskeletal tissue disorder characterized by synovial inflammation, formation of osteophytes, degeneration of cartilage, and subchondral bone sclerosis [ 1 – 3 ]. OA causes joint damage, loss of cartilage function and structure, and dysregulation of anti-inflammatory and proinflammatory pathways [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of Naringin on Monosodium Iodoacetate-Induced Osteoarthritis Pain in Rats

Zhang

Sun

2017

Med Sci Monit

View full text Add to dashboard Cite

BackgroundThe aim of the current study was to evaluate the anti-osteoarthritic and anti-inflammatory effect of naringin in a monosodium iodoacetate (MIA)- induced osteoarthritis (OA) model in rats. The anti-osteoarthritic potential of naringin was evaluated against the MIA-induced OA rat model.Material/MethodsWistar rats were used for the study and were divided into the following groups: normal control (saline-treated); group II (MIA-treated): group III (MIA+Naringin), and group IV (MIA+Indomethacin). The potential effect of naringin was evaluated via its effect on the level of proinflammatory cytokines, measuring the weight-bearing distribution, and histopathological analysis.ResultThe anti-inflammatory effect of naringin was assessed in vitro in lipopolysaccharide-induced RAW 264.6 cells. The results suggest that naringin exerts an anti-inflammatory effect via reducing the production of the prostaglandin E2 (PGE2), nitric oxide (NO), interlukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in LPS-induced RAW cells. Additionally, naringin also supported the recovery of hind-limb weight-bearing, reduced the generation or production of inflammatory mediator and proinflammatory cytokines, and protected the tissue from the damage in the OA model.ConclusionsNaringin appears to be an effective therapeutic drug for the treatment of the OA and OA-related symptoms.

show abstract

“…Rheumatoid arthritis (RA) is an autoimmune inflammatory disease characterized by erosion of the cartilage and bone, by synovial hyperplasia, pain and swelling, and even joint deformity [1]. The hyperproliferation and infiltration of synovial cells are caused by the proinflammatory cytokines and other inflammatory mediators, such as TNF-a, IL-1β, IL-6, which are secreted from macrophages, T cells, and B cells [2]. Moreover, the cartilage and bone damage is caused by osteoclasts, activated synovial fibroblasts and chondrocytes in inflammatory arthritis [3].…”

Section: Introductionmentioning

confidence: 99%

Novel Carboxylated Chitosan-Based Triptolide Conjugate for the Treatment of Rheumatoid Arthritis

et al. 2020

View full text Add to dashboard Cite

A new platform for triptolide (TP) delivery was prepared by conjugating TP to a carboxylmethyl chitosan (CMCS). Compared with the natural TP, the TP-conjugate (TP-CMCS) containing TP of ~5 wt% exhibited excellent aqueous solubility (>5 mg/mL). Results of in vitro experiments showed that TP-CMCS could relieve TP-induced inhibition on RAW264.7 cells and apoptosis, respectively. Compared with the TP group, TP-CMCS could effectively alleviate the toxicity injury of TP and decreased the mortality rate of the mice (p < 0.05). TP-CMCS did not cause much damage to the liver (AST and ALT) and kidney (BUN and CRE) (p < 0.05). After administration, the levels of IL-6, IL-1β, and TNF-α decreased, and the arthritis detumescence percentages increased significantly, and the bony erosion degree was distinctly decreased in the TP-CMCS groups and TP group. Our results suggested that TP-CMCS was a useful carrier for the treatment of RA, which enhanced aqueous solubility of free TP and reduced drug toxicity in vitro and in vivo.

show abstract

Phytoconstituents as pharmacotherapeutics in rheumatoid arthritis: challenges and scope of nano/submicromedicine in its effective delivery

Abstract: Objectives The present review explores the therapeutic application of herbals in rheumatoid arthritis (RA) therapy, and how nano/submicromedicine can be fit in the scope of its therapeutic delivery in RA has been addressed.

Cited by 48 publications

References 87 publications

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases

Effect of Naringin on Monosodium Iodoacetate-Induced Osteoarthritis Pain in Rats

Novel Carboxylated Chitosan-Based Triptolide Conjugate for the Treatment of Rheumatoid Arthritis

Contact Info

Product

Resources

About